Search Results

You are looking at 21 - 30 of 108 items for :

  • "Bladder cancer" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Joshua I. Warrick

Pathologists have identified many bladder cancer (BCA) histomorphologies that differ from conventional urothelial carcinoma (UC; also known as transitional cell carcinoma ). Several of these histologic variants are biologically aggressive, and

Full access

Stephen A. Brassell and Ashish M. Kamat

. Jemal A Siegel R Ward E . Cancer statistics, 2006 . CA Cancer J Clin 2006 ; 56 : 106 – 130 . 2. Heney NM Ahmed S Flanagan MJ . Superficial bladder cancer: progression and recurrence . J Urol 1983 ; 130 : 1083 – 1086 . 3

Full access

Richard S. Matulewicz, Brendan T. Frainey, Daniel T. Oberlin, and Joshua J. Meeks

Background The current treatment paradigm for non–muscle-invasive bladder cancer (NMIBC) is directed at reducing cancer recurrence and preventing disease progression to more advanced stages. Historically, this has been accomplished through the

Full access

Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud, and Brant A. Inman

Currently, 2.4% of all people born in the United States will develop bladder cancer during their lifetime. 1 In 2012, the estimated incidence of bladder cancer was 73,510, with a 3:1 male-to-female ratio, and accounted for 14,880 deaths. 1 At

Full access

Presenter: Arlene O. Siefker-Radtke

There have been many randomized trials trying to improve on outcomes with the M-VAC (methotrexate/vinblastine/doxorubicin/cisplatin) regimen in the treatment of urothelial bladder cancer; however, according to Arlene O. Siefker-Radtke, MD

Full access

Peter E. Clark

of this promise is in bladder cancer. Within the past 4 years, at least 4 different groups have independently tested the expression profile of locally advanced bladder cancers (typically those undergoing radical cystectomy) and assigned a molecular

Full access

Hideki Furuya and Charles J. Rosser

“…for whom the bell tolls, It tolls for thee.” - John Donne The article, “It May be Time to Abandon Urine Tests for Bladder Cancer” 1 reinforces what is widely known within urology: that current urine-based assays for the diagnosis of

Full access

Joseph J. Fantony and Brant A. Inman

Bladder cancer is the second most common malignancy of the genitourinary tract and fifth most common malignancy overall in the United States. 1 The current standard for diagnosis and surveillance of bladder cancer includes a combination of

Full access

Saurabh Parasramka, Quan Chen, Bin Huang, Peng Wang, and Zin Myint

Background: Non-metastatic muscle invasive bladder cancer (MIBC) is treated with radical cystectomy and survival is closely associated with final pathologic staging. For patients undergoing primary surgery there is evidence that delay > 90 days

Full access

Shree Vishnu Siddarth, Ginil Kumar Pooleri, and Georgie Mathew

Introduction: The recurrence following a transurethral resection (TUR) of non-muscle invasive bladder cancer (NMIBC) remains relatively high. A single immediate postoperative instillation of mitomycin C (MMC) reduces the rate of recurrence in the